Minnelide Drug Asset Due Diligence Report 2026

This Minnelide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Minnelide can convert its Small molecule drug profile and CIC x DUX4 x HSP70 heat-shock proteins biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Minnelide (query alias: Minnelide)
Modality / target	Small molecule drug; CIC x DUX4 x HSP70 heat-shock proteins; CIC inhibitors, DUX4 inhibitors, HSP70 heat-shock proteins inhibitors
Highest global status	Phase 2
Originator	Minneamrita Therapeutics LLC
Active developers	Princess Margaret Cancer Centre, Minneamrita Therapeutics LLC, University Health Network

The MCP disease footprint includes Stomach Cancer, Ewing Sarcoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05566834	Phase 1	Unknown status	36	Primary endpoint not disclosed in English source
NCT05557851	Phase 1	Unknown status	36	Primary endpoint not disclosed in English source
NCT04896073	Phase 2	Completed	16	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase II Trial of the Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)

Phase 2; n=16; evaluation: Not stated in English source. Reported fields: CR = 0 % (95%CI, 0 - 0)

Phase II study of Minnelide for patients with adenosquamous carcinoma of the pancreas (ASCP)

Phase 2; n=12; evaluation: Negative. Reported fields: OS = 16 Week ( 2 - 74+)

A phase 1 study to evaluate the safety and preliminary efficacy of minnelide given alone or in combination with paclitaxel in advanced gastric cancer.

Phase 1; n=not disclosed; evaluation: Positive. Reported fields: TRAE(Grade ≥3 AEs) = The most common were neutropenia (19.4%) and abdominal pain (11.1%) Pts ; TRAE(Grade ≥3 AEs) = The most common were neutropenia (19.4%) and abdominal pain (11.1%) Pts

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Minnelide addresses Stomach Cancer, Ewing Sarcoma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned matched transaction record(s) under the scope “target-level comparable: CIC x DUX4 x HSP70 heat-shock proteins.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: CIC x DUX4 x HSP70 heat-shock proteins records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
No matched asset or comparable transaction returned.

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Drug combination for treatment of gastric cancer”. The milestone feed surfaced a patent-application signal described as “Drug combination for treatment of gastric cancer”. The milestone feed surfaced a patent-application signal described as “Drug combination for treatment of pancreatic cancer”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO